Spartan Micro Announces Appointment of Dr. Satoshi Tateshima to its Medical Advisory Board

Share Article

Spartan Micro, Inc., a neurovascular device company, announced the appointment of Satoshi Tateshima, M.D., D.M.Sc to its Medical Advisory Board.

Spartan Micro, Inc.,, a neurovascular device company, announced the appointment of Satoshi Tateshima, M.D., D.M.Sc to its Medical Advisory Board. In this role, Dr. Tateshima will provide knowledge, insight and advice regarding the following:

  • Testing and feedback analysis of prototype and late stage proprietary technologies;
  • Prioritizing and implementing product development and initiatives;
  • Clinical activities; and,
  • Long-range strategy for achieving its mission to create safer more effective neurovascular products.

“I am excited to welcome Dr. Tateshima to the Spartan Micro team,” said Eric Stoppenhagen, Chief Executive Officer of Spartan Micro. “He brings a wealth of experience and innovation in interventional neuroradiology and he will be an invaluable asset to Spartan Micro as we focus on developing company products and sales in the global market place.”

“I am pleased to be collaborating with Spartan Micro, a company whose cutting-edge technology and products have the potential to truly be a game changer for patients with neurovascular disease,” said Dr. Tateshima. “I look forward to working with the team to advance Spartan Micro’s position and products within the neurovascular space.”

About Satoshi Tateshima, M.D., D.M.Sc
Dr. Tateshima specializes in acute stroke interventions and aneurysm embolization using state-of-the-art, minimally invasive image-guided techniques to treat strokes and aneurysms and he is also an associate professor of interventional neuroradiology. He has filed multiple patents on new intracranial stent coating and intracranial stent delivery systems and is currently involved in multiple approval studies of neuro-interventional devices. His research interests have focused on cerebrovascular diseases, biorheology of intracranial aneurysms and new neuro-endovascular device development. He received his medical degree from Jikei University School of Medicine and has been in practice for more than 20 years.

About Spartan Micro, Inc.
Spartan Micro is a neurovascular medical device company based out of San Francisco, California, USA. Its focus is research and development, production and sale of medical devices that include coil embolics, over-the-wire, flow-guided microcatheters, guiding catheters, neurovascular stents and flow diversion stents.

Spartan Micro is currently developing mechanically detachable embolic coils for the occlusion of cerebral aneurysms. In addition to treating cerebral aneurysms, its coils will also be indicated for use in the peripheral vascular anatomy for occlusion or flow diversion for other vascular deformities.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction.

Investor Relations:
Spartan Micro, Inc.
Eric Stoppenhagen
Chief Executive Officer
Phone: 1- 512-270-8501
Email: info(at)SpartanMicro(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Eric Stoppenhagen
Spartan Micro, Inc.

Visit website